Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06130020 · ClinicalTrials.gov registry record · NA

Comparing Targets of Expressive Writing

A NA study, sponsored by Trustees of Princeton University.

Completed
Registry status
NA
Development phase
160
Enrollment target

NCT06130020: Completed NA study, sponsored by Trustees of Princeton University.

NCT06130020 is a NA study that has completed, run by Trustees of Princeton University. The registered enrollment target is 160 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (89% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06130020, a NA study, has completed, sponsored by Trustees of Princeton University.

COMPLETED
Registry status
NA
Development phase
160 participants
Enrollment target

Study Summary

Expressive writing involves writing about one's deepest thoughts and feelings surrounding an emotional event. The current literature on the efficacy of expressive writing is mixed and warrants further investigation into how, when, and for whom expressive writing is an effective intervention. The goal of this study is to compare the efficacy of expressive writing interventions in young adults when people imagine that they're writing to themselves vs. a loved one. Participants will carry out an expressive writing exercise for 14 consecutive days. Participants are randomized into 3 groups: Self, Other, and Control. The Self group is instructed to write as if they were talking to themselves. The Other group is instructed to direct their writing to someone they feel close to. The Control group is asked to write down a factual description of their routine that day, and direct this writing to themselves. We will recruit participants until we have usable data from 53 participants per group (i.e., 159 in total).

Primary Outcome

Generalized Anxiety Disorder-7 (GAD-7). Scores range from 0-21, with higher scores indicating more severe anxiety.

Interventions

  • BEHAVIORAL Factual Writing
  • BEHAVIORAL Expressive Writing: Self
  • BEHAVIORAL Expressive Writing: Other

Trial Details

FieldValue
Enrollment Target 160 participants
Start Date 2023-11-10
Est. Completion 2025-10-30
Phase NA
Trustees of Princeton University

4 total trials

What the finished NCT06130020 record still lists

NCT06130020 is an interventional study that assigns participants to a tested intervention. The registered 160 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (89% lower).

The record links to 0 conditions, and to 3 interventions - of which Factual Writing is the first listed.

NCT06130020 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT06130020 about?

NCT06130020 is a clinical study titled "Comparing Targets of Expressive Writing". Expressive writing involves writing about one's deepest thoughts and feelings surrounding an emotional event. The current literature on the efficacy of expressive writing is mixed and warrants further investigation into how, when, and for whom expressive writing is an effective intervention. The goa...

What is the current status of trial NCT06130020?

This trial is currently completed. It is a NA study. The enrollment target is 160 participants. The study started on 2023-11-10. Estimated completion is 2025-10-30.

What interventions are being tested in trial NCT06130020?

The interventions under investigation include: Factual Writing (BEHAVIORAL), Expressive Writing: Self (BEHAVIORAL), Expressive Writing: Other (BEHAVIORAL).

Who is sponsoring clinical trial NCT06130020?

This trial is sponsored by Trustees of Princeton University, which has 4 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT06130020's enrollment target sits among peer trials

160 628th of 2000 higher than 1,347 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00501826 · 160 participants · Phase 2

    Combination Chemotherapy and Nelarabine in Treating Patients With T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

  • NCT00932139 · 160 participants · NA

    Effect of Electro-Acupuncture on Blood Pressure

  • NCT00992901 · 160 participants · Early Phase 1

    Role of Neural and Hormonal Regulation Factors on Insulin Secretion After Gastric Bypass Surgery

  • NCT01515527 · 160 participants · Phase 2

    Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06130020, the US trial registry maintained by the National Library of Medicine. NCT06130020 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.